Detall de la convocatòria


Objectiu de la convocatòria
The Treat FTD fund aims to support programs testing drugs or devices for FTD disorders while building clinical data around novel FTD mechanisms in human disease and corresponding biomarker endpoints in response to treatment.
Característiques principals
The fund aims to de-risk clinical programs by supporting clinical trials with clear go/no-go criteria and if positive, sufficient data to encourage follow on funding of the approach. Programs will be considered that test novel or repurposed drug candidates or devices in phase 1 or phase 2 clinical trials for FTD disorders, led by academic researchers or biotechnology companies. Both disease-modifying and symptomatic approaches will be accepted.
The RFP seeks to support clinical trials with:
  • biological mechanisms that have a sound scientific rationale for FTD
  • suitable clinical trial designs, that may include features such as basket trials, adaptive study designs or other novel approaches
  • biomarkers that can indicate target engagement and/or downstream pharmacologic effects
  • biomarker endpoints that can provide a deeper understanding of the drug mechanism and disease progression
  • therapeutics applicable to both sporadic and genetic forms of FTD
    Although the strongest proposals will address all these aspects, any approach with a sound biological rationale and well justified outcome measures for the patient population will be considered.
  • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: Ext.: 1576
    Carol Barnwell: Ext.: 1670
    Convocatòria (URL)
    Informació addicional
    Letter of Intent: January 27th, 2023
    Full Proposal: March 17th, 2023
    Up to $2,000,000 based on stage and scope of the trial. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and patient enrollment.


    The Treat FTD Fund _ Alzheimer's Drug Discovery Foundation.pdf